Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant toripalimab + docetaxel + cisplatin in locally advanced oral squamous cell carcinoma
ChiCTR2400082112Phase 2Recruiting
- Sponsor
- Affiliated Stomatological Hospital of Nanjing Medical University
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Oral Mucosal Carcinoma, sponsored by Affiliated Stomatological Hospital of Nanjing Medical University. Primary endpoints: Pathological response and The Response Evaluation Criteria in Solid Tumors (RECIST). Started Mar 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2400082112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082112.